Effect Of Adding Intravenous Midazolam To A Dual Post Operative Nausea And Vomiting Regimen In Female Patients Undergoing Laparoscopic Surgeries - A Prospective Randomized Control Trial.

This prospective randomized controlled trial evaluates the effect of adding intravenous midazolam to a dual antiemetic regimen for preventing postoperative nausea and vomiting PONV in female patients undergoing laparoscopic surgeries PONV is a common and distressing complication with an incidence of 60 to 80 percent in high-risk patients Standard prophylaxis includes dexamethasone and ondansetron however PONV remains significant despite dual therapy Midazolam a short acting benzodiazepine has demonstrated additional antiemetic properties via GABA mediated mechanisms

A total of 200 ASA I and II female patients 18 to 65 years will be randomized into two groups Group A will receive dexamethasone 8 mg with ondansetron 4 mg, while Group B will receive dexamethasone 4 mg ondansetron 4 mg and midazolam 0.04 mg/kg maximum 2 mg PONV incidence within 24 hours is the primary outcome Secondary outcomes include severity VAS rescue antiemetic requirement pain scores sedation patient satisfaction and blood glucose levels The study hypothesizes that midazolam addition significantly reduces PONV incidence and severity